@novaremed.com
Novaremed AG is a clinical-stage Swiss biopharmaceutical company.
📢
Find anything inaccurate?
If you spot any mistakes on this brand profile, report to us.
Brand Logos
View allLogo
PNG
About
Description
Novaremed is a clinical-stage biopharmaceutical company that specializes in innovating chronic pain management. They offer effective and safe treatment options as an alternative to opioids, addressing the high unmet patient and societal needs for better relief from pain and peripheral neuropathy associated with diabetes and cancer chemotherapy. The company's lead product, NRD.
E1, is an orally active non-opioid small molecule with a novel mechanism of action. It has received FDA Fast Track Designation and is currently being studied in an NIH-sponsored Phase 2b clinical trial for the treatment of painful diabetic peripheral neuropathy (PDPN) as part of the NIH HEAL initiative. Novaremed's pipeline also includes clinical candidate MP-101, which is being developed for the prevention of chemotherapy-induced peripheral neuropathy (CIPN), and MP-103, targeting CIPN and other peripheral neuropathy indications.
With a commitment to providing novel, non-opioid chronic pain therapies, Novaremed aims to counter overreliance on addictive treatments and improve the quality of life for patients suffering from chronic pain and neuropathy
Company Type
Privately Held
Company Size
2-10
Year Founded
2017
Brand collections
View allLogos
Colors
Fonts
Images
Our mission is to keep every brand on-brand everywhere 👋
All services online